News
We send the latest information from SMC Laboratories.
Introducing our new model: DDC-induced liver injury model
We introduce the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced liver injury model*, a well-known model of cholestatic liver disease and a new model we have started offering our services as. Using the DDC-induced liver injury model, cholangitis and liver fibrosis can be assessed as follows. As well as the DDC-induced liver injury model described above, we…
Introducing our new model: Liver Orthotopic Xenograft mouse model
We’re getting in touch today with an announcement regarding the addition of the Liver Orthotopic Xenograft mouse model to our model line-up – a cancer model that also allows the evaluation of the tumor microenvironment. The number of deaths from cancer continues to rise as medical advances extend life spans. Therefore, there is a…
Pre-clinical studies for cirrhosis: Carbon tetrachloride (CCl4)-induced liver fibrosis
The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region. While our STAM™ model develops mild liver fibrosis, the CCl4 model develops severe cirrhosis-like fibrosis. We also offer pharmacological studies with the positive control ”Valsartan”. As its study period is relatively short, only 4 weeks, the model…
Positive control for UUO kidney fibrosis
We are excited to share with you an update about a newly established positive control – an ALK5 inhibitor – for our UUO-induced renal fibrosis model. This ALK5 inhibitor has an inhibitory effect on the TGF-beta/ALK5 signaling pathway, which plays a central role in renal fibrosis. Below is the result of fibrosis analysis from…
New services using acute liver failure a rodent model
We are pleased to announce today the launch of new services using a mouse model for acute liver failure (ALF), TAA-induced ALF model. LEARN MORE…